Recent Conformetrix News

November 2011

Conformetrix win Emerging Biomedical Technology Project of the Year (Sponsored by Waters) at the Bionow Annual Awards Dinner, which took place on 24th November 2011 at The Mere Golf and Country Club.

September 2011

Conformetrix closes substantial funding round and starts work on early-stage drug-discovery programmes using its unqiue technology.

June 2011

Conformetrix moves to larger premises in central Manchester to support growth.

April 2011

Meet Conformetrix! We attended the BioTrinity Conference in Newbury (14-17 Apr 2011).

February 2011

Conformetrix demonstrates its novel ligand-based approach to discovery is effective for both ion-channel and GPCR targets.

November 2010

Conformetrix present their early stage Alzheimer's program at the prestigious Neuropharmacology meeting in San Diego.

September 2010

Read about Conformetrix's powerful new ligand-based discovery platform in the September edition of leading industry journal SP2.

July 2010

Conformetrix receive further investment capital from Aquarius Equity Partners to accelerate growth.

June 2010

Conformetrix identifies novel lead chemistries for the alpha-7 nicotinic acetyle choline receptor (a7-nAChR), a key pharmaceutical target in both Alzheimer's disease and schizophrenia.